Rosario Augustin, APRN
Psychiatric/Mental Health, Adult · Honolulu, HINPI 1356684658
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 28.8% of the total.
Across 174 payments — averaging $52.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$784
- Otsuka America Pharmaceutical, Inc.$707
- E.r. Squibb & Sons, L.L.C.$452
- plus $2K from 7 others
What the payments were for
- Food & beverage$9,119100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $2,623 |
| Alkermes, Inc. | 35 | $1,746 |
| Neurocrine Biosciences, Inc. | 21 | $1,255 |
| Teva Pharmaceuticals USA, Inc. | 11 | $784 |
| Otsuka America Pharmaceutical, Inc. | 28 | $707 |
| E.r. Squibb & Sons, L.L.C. | 6 | $452 |
| Johnson & Johnson | 5 | $440 |
| Axsome Therapeutics, Inc. | 4 | $361 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $208 |
| Sunovion Pharmaceuticals Inc. | 5 | $152 |
| Vanda Pharmaceuticals Inc. | 3 | $145 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $137 |
| Lundbeck LLC | 5 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,692
- LYBALVI$1,904
- VRAYLAR$1,695
- INGREZZA$796
- ARISTADA INITIO$565
- UZEDY$476
- INVEGA SUSTENNA$403
- COBENFY$285
- REXULTI$243
- Auvelity$239
- Austedo XR$231
- CAPLYTA$144
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- INVEGA TRINZA$125
- Fanapt$125
How this compares
Too few psychiatric/mental health, adult providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $170,159 |
| Invega SustennaPaliperidone Palmitate | 34 | $123,819 |
| AristadaAripiprazole Lauroxil | 35 | $81,655 |
| VraylarCariprazine Hcl | 24 | $44,325 |
| Abilify MaintenaAripiprazole | 13 | $37,864 |
| Aripiprazole | 27 | $4,157 |
| Bupropion XlBupropion Hcl | 41 | $1,174 |
| Lamotrigine | 45 | $1,004 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $990 |
| Fluoxetine Hcl | 16 | $754 |
| Hydroxyzine Pamoate | 23 | $731 |
| Prazosin Hcl | 12 | $599 |
| Quetiapine Fumarate | 29 | $508 |
| Topiramate | 12 | $503 |
| Benztropine Mesylate | 31 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,255 | $170,15921 claims |
| Johnson & JohnsonInvega Sustenna | $440 | $123,81934 claims |
| Alkermes, Inc.Aristada | $1,746 | $81,65535 claims |
| AbbVieVraylar | $2,623 | $44,32524 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $707 | $37,86413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Honolulu
- Michael PalazzoHonolulu$63K
- Stacy KracherHonolulu$3K
- Vickie GleedHonolulu$492
- Mary MossmanHonolulu$317
- Joseph GiovannoniHonolulu$249
- Jere GrahamKapaa$267
- Suwan McGrathWailuku$102
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.